Aigen Investment Management LP Trims Stock Position in Repligen Co. (NASDAQ:RGEN)

Aigen Investment Management LP cut its position in Repligen Co. (NASDAQ:RGEN) by 55.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,275 shares of the biotechnology company’s stock after selling 4,106 shares during the quarter. Aigen Investment Management LP’s holdings in Repligen were worth $487,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Repligen by 0.4% during the first quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock valued at $937,994,000 after buying an additional 21,719 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after acquiring an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC boosted its position in shares of Repligen by 26.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after acquiring an additional 199,322 shares during the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Repligen by 240.5% during the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock worth $75,866,000 after purchasing an additional 425,061 shares in the last quarter. Finally, New York State Common Retirement Fund increased its position in shares of Repligen by 14.4% in the third quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock worth $84,387,000 after purchasing an additional 71,274 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Price Performance

Shares of Repligen stock opened at $142.43 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The business’s 50 day simple moving average is $141.59 and its two-hundred day simple moving average is $144.78. The stock has a market capitalization of $7.98 billion, a P/E ratio of -384.94, a price-to-earnings-growth ratio of 4.27 and a beta of 0.96. Repligen Co. has a one year low of $113.50 and a one year high of $211.13.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The business’s revenue was up 9.7% on a year-over-year basis. During the same quarter last year, the business earned $0.23 earnings per share. Analysts forecast that Repligen Co. will post 1.45 EPS for the current year.

Insider Activity

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This represents a 13.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

RGEN has been the subject of a number of research reports. Benchmark reissued a “hold” rating on shares of Repligen in a research note on Monday, August 5th. UBS Group cut their target price on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Stephens restated an “overweight” rating and set a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. Wells Fargo & Company started coverage on Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective for the company. Finally, StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.